Navigation Links
Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
Date:12/11/2009

Therapure to provide specialized formulation and fill services

(PRWEB) December 11, 2009 -- Therapure Biopharma Inc. today announced the signing of an exclusive supply agreement with Akorn Inc. (NASDAQ: AKRX). This agreement will support Akorn’s new product development initiatives.

Under the terms of the partnership, Therapure Biopharma will provide product formulation, process development, and sterile fill/finish services to support the development of new hospital products by Akorn. Therapure Biopharma will provide these services in its Health Canada licensed facility in Mississauga, Ontario.

“We are proud that Akorn has chosen Therapure Biopharma as a strategic partner for the development of these new products,” said Thomas Wellner President and CEO of Therapure Biopharma Inc. “Therapure Biopharma has experience in meeting the needs of customers for specialized fill/finish services and we were able to respond quickly to Akorn’s particular requirements.”

“Akorn carries a broad catalogue of sterile specialty pharmaceutical products”, said Sean Brynjelsen, Akorn’s Vice President of New Business Development. “Therapure Biopharma was able to quickly respond to our need for specialty formulation and fill/finish services. The signing of this exclusive supply agreement reinforces Akorn’s commitment to expanding our portfolio through partnering.”


About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.

For more information, please visit www.akorn.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/12/prweb3316884.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
3. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
6. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
9. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
10. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
11. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
(Date:1/20/2017)... ... ... and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is ... a devoted woman of faith. , “Becoming a parent changes you. In my case, ... for years, but actually doing it might have been a while in coming if it ...
(Date:1/20/2017)... ... , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of ... Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native who ... Hardy , “While sitting up in bed, I felt a pounding headache. It was ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 ... and Others The global anti-obesity drugs market ... first half of the forecast period and CAGR of 38.7% in ... to grow at a CAGR of 32.8% from 2016 to 2027. ... in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
Breaking Medicine Technology: